Vontobel Holding’s Viking Therapeutics VKTX Stock Holding History

Vontobel Holding’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-6,059	Closed	-$384K	–	1181
2024 Q3	$384K	Buy	6,059 +915	+18%	+$53.7K	﹤0.01%	858
2024 Q2	$273K	Buy	+5,144	New	+$337K	﹤0.01%	915

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Vontobel Holding's VKTX Position: Q4 2024 in Review

Vontobel Holding sold out of Viking Therapeutics (VKTX) in Q4 2024, closing a stake of 6,059 shares — an estimated $384K sold.

Vontobel Holding first reported a position in VKTX in Q2 2024 and held it in 2 quarters. The position peaked at $384K in Q3 2024. 409 funds tracked by Wall St. Rank hold VKTX as of Q4 2024.

Vontobel Holding reported no remaining Viking Therapeutics position as of Q4 2024 after selling out during the quarter.
Vontobel Holding sold 6,059 Viking Therapeutics shares in Q4 2024, an estimated $384K.
Vontobel Holding first reported a position in Viking Therapeutics in Q2 2024 and held it in 2 quarters.
Vontobel Holding's Viking Therapeutics position peaked at $384K in Q3 2024.
409 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2024.

Based on Vontobel Holding's 13F filing for Q4 2024, filed 30 Jan 2025.